ABSTRACT
Objective Chemotherapy-related cognitive changes following breast cancer are commonly reported; however, changes in brain dynamics of large-scale neural networks remain unclear. Using data from the Aerobic exercise and CogniTIVe functioning in women with breAsT cancEr (ACTIVATE) trial, we conducted exploratory analyses to compare self-reported and objective measures of cognition and applied microstate analysis to resting state electroencephalography (EEG) data of women with breast cancer before and following chemotherapy treatment.
Methods Data from 8 female participants between the ages of 30 and 52 (mean age = 44.8 yrs, SD = 7.3 yrs) were analyzed. Cognitive function was assessed using the PROMIS (Patient-Reported Outcomes Measurement Information System) and the Trail Making Test (TMT). Five minutes of resting state, eyes-closed EEG data were also collected. Seven EEG microstates were extracted and mean microstate duration and occurrence were computed.
Results Following chemotherapy, there was a significant decrease in the PROMIS score (p = 0.003, d = 1.601), but no significant difference in the TMT. Overall, durations of microstates were significantly longer (p < 0.001, d = 2.837) and less evenly distributed following chemotherapy. The mean duration of microstate D significantly increased following chemotherapy (p = 0.007, d = 1.339). No significant correlations between microstate features and the PROMIS score were observed.
Conclusions We observed self-reported cognitive impairment and disturbed functional dynamics in the resting state brain following chemotherapy treatment. These results introduce a potential novel biomarker to evaluate the changes in large scale brain dynamics related to the cognitive effects of chemotherapy.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
This trial was registered with the ClinicalTrials.gov database (NCT03277898; September 11, 2017).
Clinical Protocols
https://pubmed.ncbi.nlm.nih.gov/32736542/
Funding Statement
The ACTIVATE trial is funded by the Canadian Cancer Society Research Institute and the AVON foundation awarded to KLC and JB.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics approval was granted by the research ethics boards at the University of Ottawa (Ottawa, ON) and the University of British Columbia (Vancouver; BC), as well as relevant hospital research ethics committees (i.e., Ottawa Health Science Network, the Royal Ottawa Mental Health Centre, and the BC Cancer research ethics boards). All participants received written and oral information prior to participation and provide informed consent.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
